ECONOMIC EVALUATION OF LONG ACTING ANTIPSYCHOTIC INJECTION IN SCHIZOPHRENIA

Long acting injection anti-psychotics (LAIs) are suggested in management of schizophrenia with oral medication non-adherence. Four of first generation LAIs; Haloperidol dec, Flupentixol dec, Flupenazine dec . and Zuclopentixol dec., are listed in national list of essential medicine except two of newer second generation LAIs.; Paliperidone LAI, and Risperidone LAI. Economic evaluation evidence of these medications may not only guide healthcare profession to choose LAIs for their patients appropriately but also support healthcare policy makers...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.